Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 173

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 173
---
 efficacy results between different clinical trials of the same product candidate due to numerous
factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes
in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. Any clinical trials that we
may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidate.

The results of
preclinical studies and early-stage clinical trials may not be predictive of future results. Initial success in clinical trials may not
be indicative of results obtained when these trials are completed or in later-stage trials.

The results of preclinical
studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not
be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative
of results obtained when such trials are completed. In particular, the small number of patients in our planned early clinical trials may
make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results
of our initial clinical trials for XPro may not be predictive of the results of further clinical trials of this drug candidate or any
of our other drug candidates. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and
many companies that have believed their drug candidates performed satisfactorily in preclinical studies and clinical trials nonetheless
have failed to obtain marketing approval of their products. Our future clinical trials may not ultimately be successful or support further
clinical development of any of our drug candidates. There is a high failure rate for drug candidates proceeding through clinical trials.
A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even
after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business,
results of operations, financial condition and prospects.

Interim top-line
and preliminary data from our planned clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may
publish interim top-line or preliminary data from our planned clinical trials. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient
data